Indication
Arteriosclerotic parkinsonism
Arteriosclerotic parkinsonism, historically referred to as vascular parkinsonism or arteriosclerotic pseudoparkinsonism, is a secondary parkinsonian syndrome of the central nervous system predominantly affecting older adults with underlying cerebrovascular disease. Read more about Arteriosclerotic parkinsonism
90 drugs 70 manufacturers
Drugs that treat it
Common Arteriosclerotic parkinsonism therapies.
TRIHEXYPHENIDYL HCL
TRIHEXYPHENIDYL HCL
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
BENZTROPINE (benztropine mesylate)
BENZTROPINE (benztropine mesylate)
BENZTROPINE (benztropine mesylate)
COGENTIN (benztropine mesylate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonArteriosclerotic parkinsonism, historically referred to as vascular parkinsonism or arteriosclerotic pseudoparkinsonism, is a secondary parkinsonian syndrome of the central nervous system predominantly affecting older adults with underlying cerebrovascular disease.
It is pathophysiologically characterized by ischemic injury—such as diffuse subcortical white matter ischemia and lacunar infarcts within the basal ganglia—that disrupts frontal-subcortical and striato-pallido-thalamocortical motor networks.
Clinically, it manifests as a symmetrical, lower-body parkinsonism characterized by early gait impairment, postural instability, and frequent falls, typically with an absence of resting tremor and poor responsiveness to dopaminergic therapy.
Associated neurological features frequently include pyramidal tract signs, pseudobulbar palsy, urinary dysfunction, and subcortical cognitive decline.
- nih.gov
Arteriosclerotic parkinsonism, historically referred to as vascular parkinsonism or arteriosclerotic pseudoparkinsonism, is a secondary parkinsonian syndrome of the central nervous system predominantly affecting older adults with underlying cerebrovascular disease
- nih.gov
Arteriosclerotic parkinsonism, historically referred to as vascular parkinsonism or arteriosclerotic pseudoparkinsonism, is a secondary parkinsonian syndrome of the central nervous system predominantly affecting older adults with underlying cerebrovascular disease It is pathophysiologically characterized by ischemic injury—such as diffuse subcortical white matter ischemia and lacunar infarcts within the basal ganglia—that disrupts frontal-subcortical and striato-pallido-thalamocortical motor net...
- myparkinsonsteam.com
Arteriosclerotic parkinsonism, historically referred to as vascular parkinsonism or arteriosclerotic pseudoparkinsonism, is a secondary parkinsonian syndrome of the central nervous system predominantly affecting older adults with underlying cerebrovascular disease
- nih.gov
It is pathophysiologically characterized by ischemic injury—such as diffuse subcortical white matter ischemia and lacunar infarcts within the basal ganglia—that disrupts frontal-subcortical and striato-pallido-thalamocortical motor networks Clinically, it manifests as a symmetrical, lower-body parkinsonism characterized by early gait impairment, postural instability, and frequent falls, typically with an absence of resting tremor and poor responsiveness to dopaminergic therapy
- nih.gov
Clinically, it manifests as a symmetrical, lower-body parkinsonism characterized by early gait impairment, postural instability, and frequent falls, typically with an absence of resting tremor and poor responsiveness to dopaminergic therapy Associated neurological features frequently include pyramidal tract signs, pseudobulbar palsy, urinary dysfunction, and subcortical cognitive decline
- nih.gov
Associated neurological features frequently include pyramidal tract signs, pseudobulbar palsy, urinary dysfunction, and subcortical cognitive decline
Personalize your experience
Follow Arteriosclerotic parkinsonism and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.